JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
PARSIPPANY, NJ February 24, 2011 -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products announced today that it has entered into a multi‐year contract manufacturing agreement with an undisclosed biotechnology company. JHP will be responsible for manufacturing and supply of an approved therapy used in cancer patients.
Stuart Hinchen, president and co-founder of JHP stated “We recognize that being selected to produce this crucial drug demonstrates our ability to meet critical marketplace needs. JHP was able to achieve the rigorous timelines required to manufacture this drug through a quality-driven, experienced staff and a customer‐centric approach. Additionally, our record of cGMP compliance, coupled with our experience in manufacturing site transfers put us in the position to serve this important customer.”
Hinchen also noted, “This will be the second multi-year contract JHP has entered during the last two months. These agreements are examples of how our approach to ongoing investment in our people and facilities allow us to focus on customer needs which results in rising, sustainable growth. Our Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing both clinical and commercial products.”
About JHP Pharmaceuticals, LLC
JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables, biologics, vaccines, ophthalmics and otics for large and small pharmaceutical and biotech organizations.
JHP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, four lyophilizers and a clinical fill line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.
JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit
www.jhppharma.com
Additional Press Releases
|
02/29/12 |
|
JHP Pharmaceuticals Adds Second Product
To Multi-Year Contract Manufacturing Agreement |
 |
|
Webpage
|
PDF Format |
|
|
|
|
07/25/11 |
|
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/06/11 |
|
JHP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/05/11 |
|
JHP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®,
Coly-Mycin® M and Pitocin® |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/24/11 |
|
JHP Pharmaceuticals Announces Chief
Executive Officer Succession |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
03/28/11 |
|
JHP Pharmaceuticals Announces Multi-Year
Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
02/24/11 |
|
JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
01/27/11 |
|
JHP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
06/29/10 |
|
JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
05/10/10 |
|
JHP Pharmaceuticals Announces Successful
Completion of FDA and EMEA GMP Audits |
|
|
|
Webpage
|
PDF Format |
|
|
|
|
09/28/09 |
|
JHP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
08/20/08 |
|
JHP Pharmaceuticals & SpePharm complete
purchaseof Dantrium® (dantrolene sodium)
|
|
|
|
Webpage
|
PDF Format |
|
|
|
|
07/16/07 |
|
King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility
To JHP Pharmaceuticals |
|
|
|
Webpage
|
PDF Format |
|
|
|
Return To Press & News
»
